Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver

OBJECTIVE: Bexarotene (Targretin®) is a clinically used anti-tumoral agent which exerts its action through binding to and activation of the Retinoid-X-Receptor (RXR). The most frequent side effect of bexarotene administration is an increase in plasma triglycerides, an independent risk factor of card...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Lalloyer, Fanny, Pedersen, Thomas Åskov, Gross, Barbara, Lestavel, Sophie, Yous, Saïd, Vallez, Emmanuelle, Gustafsson, Jan-Åke, Mandrup, Susanne, Fiévet, Catherine, Staels, Bart, Tailleux, Anne
Formato: Artigo
Idioma:Inglês
Publicado: Lippincott Williams & Wilkins 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2824837/
https://ncbi.nlm.nih.gov/pubmed/19592467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.109.189506
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares